Abstract 1036P
Background
PM1003 is a VHH-based anti-PD-L1 x 4-1BB bispecific antibody that exhibits PD-L1 expression-dependent 4-1BB agonism, with excellent anti-tumor activity and safety in preclinical studies.
Methods
The safety and tolerability of PM1003 in patients (pts) with advanced solid tumors were assessed during dose escalation, and pts with advanced solid tumors positive for PD-L1 expression have been enrolled for assessing anti-tumor activity during dose expansion.
Results
At the data cut-off up to Apr. 19, 2023, 23 pts had been enrolled, with 19 pts for dose escalation (3 pts for each of the 0.02, 0.1, 1, 3, 10 mg/kg dose levels and 4 pts for the 6 mg/kg dose level). All pts had prior 1-6 lines of systemic treatment. Dose-limiting toxicity (DLT) was assessed over 21 days after the first dose followed by dosing Q2W. 4 pts were enrolled for dose expansion (2 pts in 1 mg/kg, 1 patient in each of the 3 and 6 mg/kg dose levels, Q2W). No DLTs were observed during dose escalation. Treatment-related adverse events (TRAEs) occurred in 22 pts (95.7%). The most common TRAEs in pts included anemia (39.1%, Grade≥3 0%), aspartic acid aminotransferase increased (30.4%, Grade≥3 4.3%), white blood cell count decreased (30.4%, Grade≥3 8.7%) and platelet count decreased (30.4%, Grade≥3 0%). For the 1 - 10 mg/kg cohorts, T1/2 was 6.3 - 15.3 days after the first dose. PD-L1 target occupancy approach to saturation at 7 days after the first dose and maintained stable. 18 pts were evaluable for efficacy. The objective response rate was 5.6% and the disease control rate was 44.4%. Preliminary antitumor activity was observed in one PD-L1 positive gastric cancer patient (1 mg/kg, Q2W; TPS=5%, CPS=30) who was heavily treated with chemotherapy, anti-PD-1 and anti-HER2-ADC after surgery. 87.8% of tumor shrinkage was achieved in the target lesion at the first efficacy evaluation (7 weeks) after PM1003 treatment. Partial Response was confirmed at subsequent visits.
Conclusions
PM1003 was well-tolerated at doses up to 10 mg/kg and preliminary antitumor efficacy was observed in a patient with prior anti-PD-1 treatment. Expansion cohorts to evaluate efficacy and further safety in PD-L1-positive pts are ongoing.
Clinical trial identification
ChiCTR2100052887.
Editorial acknowledgement
Legal entity responsible for the study
Biotheus Inc.
Funding
Biotheus Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Presenter: Hsiu-Tzu Wang
Session: Poster session 19
1059P - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent clinical outcomes and immune responses of clear cell renal cell carcinoma
Presenter: Dingwei Ye
Session: Poster session 19
1061P - Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Presenter: María Del Mar Noblejas Lopez
Session: Poster session 19
1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Presenter: Christophe Tournigand
Session: Poster session 19
1063P - Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Presenter: Caterina Tozzi
Session: Poster session 19
1065P - Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Presenter: Federica Pecci
Session: Poster session 19
1066P - Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Presenter: Víctor Albarrán
Session: Poster session 19
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19
1068P - Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models
Presenter: Salvatore Cortellino
Session: Poster session 19